Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. 2. Juni 2013 Fontein, D.B.Y., Seynaeve, C., Hadji, P., Hille, E.T.M., van de Water, W., Putter, H., Kranenbarg, E.M.-K., Hasenburg, A., Paridaens, R.J., Vannetzel, J.-M., Markopoulos, C., Hozumi, Y., Bartlett, J.M.S., Jones, S.E., Rea, D.W., Nortier, J.W.R., van de Velde, C.J.H., 2013. J Clin Oncol 31, 2257–2264. doi:10.1200/JCO.2012.45.3068 Abstract Non-interventional study Be-1st: First line therapy with bendamustine in advanced indolent non-Hodgkin lymphoma (NHL) in treatment routine. Becker, M., Tschechne, B., Reeb, M., Schwinger, U., Bruch, H.-R., Straßl, L., 2013. haematologica, EHA (Stockholm) 98, P321. Abstract… Weiterlesen The German mRCC Registry – aims and results after the first 1000 patients. Goebell, P.J., Müller, L., Blumenstengel, K., Hübner, A., Lück, A., Vogt, M., Marschner, N., 2013. Eur Urol Suppl 2013;12;e1106 DOI:10.1016/S1569-9056(13)61581-X… Weiterlesen